53 related articles for article (PubMed ID: 38597415)
21. Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas.
Chen S; Zhang S; Wang Z; Li J; Yuan Y; Li T; Zuo M; Feng W; Li W; Chen M; Liu Y
Front Pharmacol; 2022; 13():1038272. PubMed ID: 36438805
[TBL] [Abstract][Full Text] [Related]
22. Delineating the dynamic evolution from preneoplasia to invasive lung adenocarcinoma by integrating single-cell RNA sequencing and spatial transcriptomics.
Zhu J; Fan Y; Xiong Y; Wang W; Chen J; Xia Y; Lei J; Gong L; Sun S; Jiang T
Exp Mol Med; 2022 Nov; 54(11):2060-2076. PubMed ID: 36434043
[TBL] [Abstract][Full Text] [Related]
23. Integrated analysis of multimodal single-cell data with structural similarity.
Cao Y; Fu L; Wu J; Peng Q; Nie Q; Zhang J; Xie X
Nucleic Acids Res; 2022 Nov; 50(21):e121. PubMed ID: 36130281
[TBL] [Abstract][Full Text] [Related]
24. The correlation between probiotic use and outcomes of cancer patients treated with immune checkpoint inhibitors.
Zhang L; Jin Q; Chai D; Kuang T; Li C; Guan Y; Liu L; Wang W; Deng W
Front Pharmacol; 2022; 13():937874. PubMed ID: 36110546
[No Abstract] [Full Text] [Related]
25.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
26. Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors.
Keshet R; Lee JS; Adler L; Iraqi M; Ariav Y; Lim LQJ; Lerner S; Rabinovich S; Oren R; Katzir R; Weiss Tishler H; Stettner N; Goldman O; Landesman H; Galai S; Kuperman Y; Kuznetsov Y; Brandis A; Mehlman T; Malitsky S; Itkin M; Koehler SE; Zhao Y; Talsania K; Shen TW; Peled N; Ulitsky I; Porgador A; Ruppin E; Erez A
Nat Cancer; 2020 Sep; 1(9):894-908. PubMed ID: 35121952
[TBL] [Abstract][Full Text] [Related]
27. Systematic analysis of the role of SLC52A2 in multiple human cancers.
Zhang L; Li M; Cui Z; Chai D; Guan Y; Chen C; Wang W
Cancer Cell Int; 2022 Jan; 22(1):8. PubMed ID: 34991609
[TBL] [Abstract][Full Text] [Related]
28. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data.
Maeser D; Gruener RF; Huang RS
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34260682
[TBL] [Abstract][Full Text] [Related]
29. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Pusztai L; Yau C; Wolf DM; Han HS; Du L; Wallace AM; String-Reasor E; Boughey JC; Chien AJ; Elias AD; Beckwith H; Nanda R; Albain KS; Clark AS; Kemmer K; Kalinsky K; Isaacs C; Thomas A; Shatsky R; Helsten TL; Forero-Torres A; Liu MC; Brown-Swigart L; Petricoin EF; Wulfkuhle JD; Asare SM; Wilson A; Singhrao R; Sit L; Hirst GL; Berry S; Sanil A; Asare AL; Matthews JB; Perlmutter J; Melisko M; Rugo HS; Schwab RB; Symmans WF; Yee D; Van't Veer LJ; Hylton NM; DeMichele AM; Berry DA; Esserman LJ
Cancer Cell; 2021 Jul; 39(7):989-998.e5. PubMed ID: 34143979
[TBL] [Abstract][Full Text] [Related]
30. Inference and analysis of cell-cell communication using CellChat.
Jin S; Guerrero-Juarez CF; Zhang L; Chang I; Ramos R; Kuan CH; Myung P; Plikus MV; Nie Q
Nat Commun; 2021 Feb; 12(1):1088. PubMed ID: 33597522
[TBL] [Abstract][Full Text] [Related]
31. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
32. Identification of Key Genes in Purine Metabolism as Prognostic Biomarker for Hepatocellular Carcinoma.
Su WJ; Lu PZ; Wu Y; Kalpana K; Yang CK; Lu GD
Front Oncol; 2020; 10():583053. PubMed ID: 33520699
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT).
van den Ende T; de Clercq NC; van Berge Henegouwen MI; Gisbertz SS; Geijsen ED; Verhoeven RHA; Meijer SL; Schokker S; Dings MPG; Bergman JJGHM; Haj Mohammad N; Ruurda JP; van Hillegersberg R; Mook S; Nieuwdorp M; de Gruijl TD; Soeratram TTD; Ylstra B; van Grieken NCT; Bijlsma MF; Hulshof MCCM; van Laarhoven HWM
Clin Cancer Res; 2021 Jun; 27(12):3351-3359. PubMed ID: 33504550
[TBL] [Abstract][Full Text] [Related]
34.
Zhang Y; Parmigiani G; Johnson WE
NAR Genom Bioinform; 2020 Sep; 2(3):lqaa078. PubMed ID: 33015620
[TBL] [Abstract][Full Text] [Related]
35. Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer.
Cho JW; Hong MH; Ha SJ; Kim YJ; Cho BC; Lee I; Kim HR
Exp Mol Med; 2020 Sep; 52(9):1550-1563. PubMed ID: 32879421
[TBL] [Abstract][Full Text] [Related]
36. Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma.
Zhang Q; He Y; Luo N; Patel SJ; Han Y; Gao R; Modak M; Carotta S; Haslinger C; Kind D; Peet GW; Zhong G; Lu S; Zhu W; Mao Y; Xiao M; Bergmann M; Hu X; Kerkar SP; Vogt AB; Pflanz S; Liu K; Peng J; Ren X; Zhang Z
Cell; 2019 Oct; 179(4):829-845.e20. PubMed ID: 31675496
[TBL] [Abstract][Full Text] [Related]
37. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load.
Jung H; Kim HS; Kim JY; Sun JM; Ahn JS; Ahn MJ; Park K; Esteller M; Lee SH; Choi JK
Nat Commun; 2019 Sep; 10(1):4278. PubMed ID: 31537801
[TBL] [Abstract][Full Text] [Related]
38. Maftools: efficient and comprehensive analysis of somatic variants in cancer.
Mayakonda A; Lin DC; Assenov Y; Plass C; Koeffler HP
Genome Res; 2018 Nov; 28(11):1747-1756. PubMed ID: 30341162
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers.
Birkbak NJ; Li Y; Pathania S; Greene-Colozzi A; Dreze M; Bowman-Colin C; Sztupinszki Z; Krzystanek M; Diossy M; Tung N; Ryan PD; Garber JE; Silver DP; Iglehart JD; Wang ZC; Szuts D; Szallasi Z; Richardson AL
Ann Oncol; 2018 Apr; 29(4):903-909. PubMed ID: 29452344
[TBL] [Abstract][Full Text] [Related]
40. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.
Lauss M; Donia M; Harbst K; Andersen R; Mitra S; Rosengren F; Salim M; Vallon-Christersson J; Törngren T; Kvist A; Ringnér M; Svane IM; Jönsson G
Nat Commun; 2017 Nov; 8(1):1738. PubMed ID: 29170503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
